Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with olaparib within its marketing authorisation for treating metastatic hormone-resistant prostate cancer that has progressed on one next-generation hormonal agent (abiraterone or enzalutamide) and has been treated with taxane-based chemotherapy.
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]. We have recently invited stakeholders to respond to a written consultation on the draft scope for this evaluation. The company that market pembrolizumab have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this evaluation from its current work programme, this means the consultation on the draft scope will now close. Please accept our apologies for any inconvenience. As this evaluation has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes.
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Selected
- Process:
- TA
- ID number:
- 3814
Project Team
- Project lead
- Michelle Adhemar
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 31 March 2022 | Suspended. The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]. We have recently invited stakeholders to respond to a written consultation on the draft scope for this evaluation. The company that market pembrolizumab have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this evaluation from its current work programme, this means the consultation on the draft scope will now close. Please accept our apologies for any inconvenience. As this evaluation has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes. |
| 28 February 2022 - 28 March 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 28 February 2022 | In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual